title: [Venlafaxine in the treatment of moderate and severe depressions: the ways to increase treatment efficacy].
abstract: OBJECTIVE
  To find factors influencing the efficacy of venlafaxine in moderate and severe depressions.
  
  
  METHODS
  An observational study was carried out in real clinical practice. We examined 62 patients with depression, 21 men and 41 women, aged from 19 to 61 years, treated with venlafaxine. The duration of treatment was 84 days (first at the hospital and then at home). The initial dose was 75 mg daily, mean therapeutic dose 225 mg daily. Patient's status was assessed using clinical/psychological methods and psychometric scales (MADRS, Beck scale, CGI, UKU).
  
  
  CONCLUSIONS
  The high efficacy of the drug in the treatment of severe and moderate depressions was demonstrated. Venlafaxine was mostly effective in the treatment of anxious depression and less effective for hypochondriac depression. The rapid increase in dose of venlafaxine makes it possible to reach treatment effect in shorter time without worsening drug tolerability.
authors.affiliation: Sechenov First Moscow State Medical University, Moscow.
authors.forename: N N
authors.initials: NN
authors.lastname: Ivanets
authors.affiliation: Sechenov First Moscow State Medical University, Moscow.
authors.forename: M A
authors.initials: MA
authors.lastname: Kinkulkina
authors.affiliation: Sechenov First Moscow State Medical University, Moscow.
authors.forename: Yu G
authors.initials: YG
authors.lastname: Tikhonova
authors.affiliation: Sechenov First Moscow State Medical University, Moscow.
authors.forename: T A
authors.initials: TA
authors.lastname: Iziumina
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000627:therapeutic use*; D003511:Cyclohexanols / Q000008:administration & dosage / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy* / Q000523:psychology; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride; D055815:Young Adult
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride